Global Epigenetics Market was valued at $555 million in 2016, and is estimated to reach at $1,321 million by 2023, registering a CAGR of 13.1% from 2017 to 2023. Epigenetics is an extension of genetics and developmental biology, which involves study of cellular and physiological trait variations initiated by external or environmental stimuli. Epigenetics deals with changes in gene expression caused by certain base pairs in DNA & RNA, which are “turned off” or “turned on”, through chemical reactions contrary to being affected by changes in the nucleotide sequence. Epigenetic alterations result into change in phenotype, with the genotype of the organism being constant. Epigenetics changes are influenced by different factors, such as age, surrounding environment, lifestyle, disease state, and others.

DNA methylation and histone modification for instance are epigenetic processes wherein the alteration in gene expression is observed without the change in the DNA sequence. Rise in cancer prevalence; improved funding & aids for R&D activities, surge in partnership between academic, pharmaceutical, and biotechnology companies, and increased application of epigenetics in non-oncology diseases are the key factors that propel the growth of this market.

Get Free Access to Sample Report @ https://www.alliedmarketresearch.com/request-sample/846

The epigenetics market is segmented based on product, application, end user, and geography. Based on product, it is divided into enzymes, kits & assays, instruments, and, reagents. Enzymes are further classified into DNA ligases, DNA polymerases, other DNA-modifying enzymes, acetylases, methyltransferases, other protein-modifying enzymes, reverse transcriptase, RNA ligases, and other RNA-modifying enzymes. Kits & assays are further subdivided into bisulfite conversion kits, chip-seq kits, deep sequencing kits, methyltransferase assays, histone assays, immunoprecipitation kits, and other epigenetic kits. Based on instruments, the market is further sub segmented into mass spectrometers, next-generation sequencers, qPCRs, and sonicators & other instruments. Based on reagents, it is categorized into antibodies, buffers, histones, magnetic beads, primers, and other epigenetics reagents.

On the basis of application, the market is bifurcated into oncology and non-oncology. Oncology is further sub-segmented into solid tumors & liquid tumors and non-oncology is further categorized into inflammatory diseases, metabolic diseases, infectious diseases, cardiovascular diseases, developmental biology, drug discovery, and other applications. On the basis of end user, the market is classified into academic & research institutes, pharmaceutical companies, biotechnology companies & contract research organizations (CROs). Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The market is expected to witness a moderate growth during the forecast period, owing to the rise in epigenetic drug discovery. Furthermore, surge in prevalence of cancer and technological advancements in epigenetics research are anticipated to augment the market growth. The untapped potential of emerging markets, such as China and India, is expected to present various opportunities for market expansion. However, high costs of instruments and dearth of skilled personnel are expected to hamper the market growth.

The report provides extensive competitive analysis and profiles of key market players, such as Abcam Plc., Illumina, QIAGEN N.V., Merck & Co., New England Biolabs, Inc., Epizyme Inc., Thermo Fisher Scientific, Inc., Active Motif. Diagenode, Inc., and Zymo Research Corporation.

The other players in the value chain include Domainex, CellCentric Ltd., Chroma Therapeutics Ltd., Eisai Co. Ltd., Novartis International AG, Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., and Valirx plc.

Asia-Pacific possesses high market potential for the growth of epigenetics market, owing to high incidence of cancer and rise in healthcare expenditure. This region is anticipated to experience rapid market growth due to economic development.

Get Full Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/846

India epigenetics market is projected to grow at a CAGR of 16.9% during the forecast period.

Key Benefits

This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
Market estimations are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on geography assists to understand the regional market and the strategic business planning.
The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
Epigenetics Market Key Segments:

By Product

Enzymes
DNA Ligases
DNA Polymerases
Other DNA-modifying Enzymes
Acetylases
Methyltransferases
Other Protein-modifying Enzymes
Reverse Transcriptase
RNA Ligases
Other RNA-modifying Enzymes
Kits & Assays
Bisulfite Conversion Kits
Chip-seq Kits
Deep Sequencing Kits
Methyltransferase Assays
Histone Assays
Immunoprecipitation Kits
Other Epigenetic Kits
Instruments
Mass Spectrometers
Next-generation Sequencers
qPCRs
Sonicators
Other Instruments
Reagents
Antibodies
Buffers
Histones
Magnetic Beads
Primers
Other Epigenetics Reagents
By Application

Oncology
Solid Tumors
Liquid Tumors
Non-oncology
Inflammatory Diseases
Metabolic Diseases
Infectious Diseases
Cardiovascular Diseases
Developmental Biology
Drug Discovery
Others
By End User

Academic & Research Institutes
Pharmaceutical Companies
Biotechnology Companies
Contract Research Organizations (CROs)
By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Taiwan
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA